Galectin-1 fosters an immunosuppressive microenvironment in colorectal cancer by reprogramming CD8 + regulatory T cells
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Significance: Although immune checkpoint blockade therapies have achieved long-term responses in several malignancies, in colorectal cancer (CRC) patients clinical benefit is observed only in heavily mutated tumors that are mismatch-repair–deficient or have high microsatellite instability. This limitation urges the identification of novel immune escape mechanisms and the design of additional immunotherapeutic modalities. We show that Galectin-1 (Gal-1) confers immune privilege to CRC by increasing the frequency of CD8 + CD122 + PD-1 + regulatory T cells (Tregs) and accentuating their immunosuppressive activity in experimental models. Accordingly, analysis of CRC patient datasets revealed a “poor prognosis signature” characterized by high Gal-1 expression and elevated CD8 + Treg score. Thus, targeting Gal-1/glycan interactions may represent a potential immunotherapeutic modality for treating CRC by recalibrating the CD8 + Treg compartment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · cited 3×
“CMS4 represents poorly immunogenic tumors associated with bad prognosis and characterized by high stromal infiltration, TGF-β activation, and angiogenesis (45).”
BackgroundImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Immunotherapy in colorectal cancer: Rationale, challenges and potential
Ganesh, K., Stadler, Z. K., Cercek, A., Mendelsohn, R. B., Shia, J., Segal, N. H., & Diaz, L. A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0126-x · Cited by 1,954
Lau, K. S., Partridge, E. A., Grigorian, A., Silvescu, C. I., Reinhold, V. N., Demetriou, M., & Dennis, J. W. (2007) · Cell · doi:10.1016/j.cell.2007.01.049 · Cited by 914 · cited 1×
“In this context, Gal-3 has been shown to bind to immune checkpoint molecules, including CTLA-4 and lymphocyte antigen-3 (LAG-3) on CD8 T cells, thus regulating their signaling threshold, activation and differentiation (67, 68).”
BackgroundAllen, I. C., TeKippe, E. M., Woodford, R.-M. T., Uronis, J. M., Holl, E. K., Rogers, A. B., Herfarth, H. H., Jobin, C., & Ting, J. P.-Y. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100050 · Cited by 826 · cited 1×
“5%) and 14 d of recovery, as described previously (74).”
BackgroundKouo, T., Huang, L., Pucsek, A. B., Cao, M., Solt, S., Armstrong, T., & Jaffee, E. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0150 · Cited by 531
Cited by
Zou, Y., Ye, F., Kong, Y., Hu, X., Deng, X., Xie, J., Song, C., Ou, X., Wu, S., Wu, L., et al. (2023) · Advanced Science · doi:10.1002/advs.202203699 · Cited by 278
Targeting galectin-driven regulatory circuits in cancer and fibrosis
Mariño, K. V., Cagnoni, A. J., Croci, D. O., & Rabinovich, G. A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00636-2 · Cited by 246
Self-citationGamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment
Gao, Z., Bai, Y., Lin, A., Jiang, A., Zhou, C., Cheng, Q., Liu, Z., Chen, X., Zhang, J., & Luo, P. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01722-0 · Cited by 138
Spatial resolution of cellular senescence dynamics in human colorectal liver metastasis
Garbarino, O., Lambroia, L., Basso, G., Marrella, V., Franceschini, B., Soldani, C., Pasqualini, F., Giuliano, D., Costa, G., Peano, C., et al. (2023) · Aging Cell · doi:10.1111/acel.13853 · Cited by 43
“…chemokine ligand 1 (CXCL1), known to attract macrophages and neutrophils, were significantly upregulated in mesenchymal crypts (Figure S6i,j), as well as several immunosuppression- related genes (Cagnoni et al., 2021; Chiavarina et al., 2021; Liu et al., 2018; Patry et al., 2015) (Figure 5e– g).”
BackgroundImmunotherapies targeting tumor vasculature: challenges and opportunities
Dianat-Moghadam, H., Nedaeinia, R., Keshavarz, M., Azizi, M., Kazemi, M., & Salehi, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1226360 · Cited by 36
Metadata
- Authors
- Cagnoni, A. J., Giribaldi, M. L., Blidner, A. G., Cutine, A. M., Gatto, S. G., Morales, R. M., Salatino, M., Abba, M. C., Croci, D. O., Mariño, K. V., & Rabinovich, G. A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2021-05-18
- Volume
- 118
- Issue
- 21
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W3163901426
- Cited by
- 130
- References
- 8
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Galectin-1 fosters an immunosuppressive microenvironment in colorectal cancer by reprogramming CD8 + regulatory T cells. https://app.cochat.ai/papers/10.1073/pnas.2102950118
- The paper
- Cagnoni, A. J., Giribaldi, M. L., Blidner, A. G., Cutine, A. M., Gatto, S. G., Morales, R. M., Salatino, M., Abba, M. C., Croci, D. O., Mariño, K. V., & Rabinovich, G. A. (2021). Galectin-1 fosters an immunosuppressive microenvironment in colorectal cancer by reprogramming CD8 + regulatory T cells. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2102950118
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.